Literature DB >> 4208275

Comparison of tobramycin, gentamicin, colistin, and carbenicillin in Pseudomonas sepsis in monkeys.

S Saslaw, H N Carlisle, M Moheimani.   

Abstract

Intravenous inoculation of 3.4 x 10(10) to 7.4 x 10(10)Pseudomonas aeruginosa organisms into rhesus monkeys 4 days after intravenous or intratracheal inoculation of 2.0 to 2.5 mg of vincristine sulfate resulted in fatal sepsis in eight of nine monkeys. After intramuscular administration, in two equal doses, of 5 mg of tobramycin, gentamicin, and colistin per kg per day beginning 16 hr after challenge, 4 of 11, 4 of 11, and 3 of 10 monkeys died, respectively. Administration of daily doses of 100 to 400 mg of carbenicillin per kg was followed by death in 5 of 12. Duration of illness in the surviving monkeys in each therapy group was similar. Under the conditions of this study, prior administration of vincristine sulfate resulted in a decrease in leukocytes and enhanced susceptibility to Pseudomonas infection. Using this model for studies of comparative efficacy of antibiotics, we observed comparable results after treatment with tobramycin, gentamicin, colistin, and carbenicillin.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4208275      PMCID: PMC444285          DOI: 10.1128/AAC.2.3.164

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.

Authors:  I S JOHNSON; J G ARMSTRONG; M GORMAN; J P BURNETT
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

2.  Occurrence of serious bacterial infections since introduction of antibacterial agents.

Authors:  M FINLAND; W F JONES; M W BARNES
Journal:  J Am Med Assoc       Date:  1959-08-29

3.  Antibiotics for Pseudomonas aeruginosa sepis: inadequate proof of efficacy.

Authors:  S D Davis; A Iannetta; R J Wedgwood
Journal:  J Infect Dis       Date:  1971-07       Impact factor: 5.226

4.  Nonhuman primates in evaluation of hematotoxicity.

Authors:  S Saslaw; H N Carlisle
Journal:  Ann N Y Acad Sci       Date:  1969-07-03       Impact factor: 5.691

5.  Studies on therapy of staphylococcal infections in monkeys. 3. Comparison of cephalothin, cephaloridine and cephalexin.

Authors:  S Saslaw; H N Carlisle
Journal:  Am J Med Sci       Date:  1968-09       Impact factor: 2.378

6.  Comparison of cephalothin, cephaloridine, cephalexin and cephaloglycin in streptococcal infections in monkeys.

Authors:  S Saslaw; H N Carlisle
Journal:  Am J Med Sci       Date:  1969-06       Impact factor: 2.378

7.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

8.  Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.

Authors:  S Schimpff; W Satterlee; V M Young; A Serpick
Journal:  N Engl J Med       Date:  1971-05-13       Impact factor: 91.245

9.  Pseudomonas infections in infants and children.

Authors:  L D ASAY; R KOCH
Journal:  N Engl J Med       Date:  1960-05-26       Impact factor: 91.245

10.  Effect of vincristine sulfate on Pseudomonas infections in monkeys.

Authors:  S Saslaw; H N Carlisle; M Moheimani
Journal:  Infect Immun       Date:  1972-08       Impact factor: 3.441

View more
  3 in total

1.  A clinical study on the ototoxic effects of tobramycin.

Authors:  W Lehmann; R Häusler; F A Waldvogel
Journal:  Arch Otorhinolaryngol       Date:  1976-07-20

2.  Comparison of gentamicin, carbenicillin and gentamicin, and carbenicillin in Pseudomonas sepsis in monkeys.

Authors:  S Saslaw; H N Carlisle; M Moheimani
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

3.  Comparison of colistin-carbenicillin, colistin, and carbenicillin in Pseudomonas sepsis in monkeys.

Authors:  S Saslaw; H N Carlisle; M Moheimani
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.